ATP-Binding Cassette Transporters; Blood-Brain Barrier; Central Nervous System; Drug Carriers; Drug Development; Drug Interactions; Kidney; Liver; Lung; Membrane Transport Proteins; Nuclear Medicine; Pharmacokinetics; Pharmacology, Clinical; Positron-Emission Tomography; Radionuclide Imaging; Tissue Distribution
- Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging
Head: Markus Zeitlinger
Research Area: Our main focus is the study of the drug distribution process by employing techniques to measure target site distribution directly, i.e. PET or microdialysis.
- Translational Pharmacokinetic Imaging
Head: Oliver Langer
In my research I use positron emission tomography (PET) imaging with radiolabeled drug molecules to assess factors governing the tissue distribution and excretion of drugs in health and disease with a special emphasis on the action of membrane transporters belonging to the ATP-binding cassette (ABC) and solute carrier (SLC) families. My research covers preclinical and clinical PET studies in healthy rodents, rodent disease models (Alzheimer's disease, epilepsy), healthy human volunteers and patients. I am also interested in the development of new PET imaging protocols to measure the activity of ABC and SLC transporters in different organs (brain, eye, liver, kidneys, lungs) and in the development of strategies to enhance the brain distribution of moleculary targeted anticancer drugs.
Techniques, methods & infrastructure
Preclinical and clinical positron emission tomography (PET); radiotracer development; radiochemistry; carbon-11 and fluorine-18 labelling; pharmacokinetic modeling; quantitative image analysis; in vitro transport experiments; autoradiography; metabolite analysis
- PETABC (2020)
Source of Funding: FFG (Austrian Research Promotion Agency), JPND transnational call: “Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases (JPND2020) - JPND2020-568-081
- Use of PET to study the effect of antihypertensive drugs on lung-specific expression of ACE2, the cellular entry point of SARS-CoV-2 (2020)
Source of Funding: FWF (Austrian Science Fund), Stand-alone project (Urgent Funding SARS-CoV-2) - P 33921
- A pilot study to assess the impact of ABCB1 on the neuropharmacokinetics of the weak ABCB1 substrate [11C]metoclopramide (2018)
Source of Funding: FWF (Austrian Science Fund), KLIF - KLI 694-B30
- Influence of ABCG2 SNP on brain distribution of ABCG2 substrates (2015)
Source of Funding: FWF (Austrian Science Fund), KLIF - KLI 480-B30
- PET imaging to assess BBB function in Alzheimer’s disease (2014)
Source of Funding: FWF (Austrian Science Fund), DACH project - I 1609-B24
- Species differences in Pgp function at the BBB (2012)
Source of Funding: FWF (Austrian Science Fund), stand-alone project - P24894-B24
- Euripides (2008)
Source of Funding: EU, FP7 collaborative project - grant agreement nr. 201380
- Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics. Available at: http://dx.doi.org/10.1002/cpt.2052.
- Mairinger, S. et al., 2020. Assessing the Activity of Multidrug Resistance–Associated Protein 1 at the Lung Epithelial Barrier. Journal of Nuclear Medicine, 61(11), pp.1650–1657. Available at: http://dx.doi.org/10.2967/jnumed.120.244038.
- Zoufal, V. et al., 2019. Imaging P-Glycoprotein Induction at the Blood–Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PET. Journal of Nuclear Medicine, 61(7), pp.1050–1057. Available at: http://dx.doi.org/10.2967/jnumed.119.237198.
- Bauer, M. et al., 2017. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology & Therapeutics, 104(1), pp.139–147. Available at: http://dx.doi.org/10.1002/cpt.888.
- Bauer, M. et al., 2016. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier. Clinical Pharmacology & Therapeutics, 100(2), pp.131–141. Available at: http://dx.doi.org/10.1002/cpt.362.